FEATURED

MicroRNA Down-regulate After UV Exposure

MicroRNAs in the melanocytes of women with a history of melanoma were down-regulated when exposed to ultraviolet radiation.

Immune Therapies Offer Promise

Researchers argue that immune therapies that target hormone-receptor-positive breast cancer is not the "dead end" it was once believed to be.

MM Linked to Pesticide Exposure

Exposure to the pesticides carbaryl, captan, and DDT is associated with increased risk for the development of myeloma in men.

Cellular Senescence Effects are Context-Dependent

The senescence-associated secretory phenotype can promote tumorigenesis under certain conditions, and may offer a target for senolytic therapy.

RCC: Microwave Ablation for T1 Tumors

Results from a small retrospective study showed that percutaneous microwave ablation (MWA) had a technical success rate higher than 95% for both T1a and T1b renal cell carcinomas.

NSCLC Quality Measures May Improve Outcomes

New study suggests a wide variability in compliance with quality measures in the treatment of stage IIIA non-small cell lung cancer (NSCLC).

Biomarker Indicates Benefit from Cetuximab

Cetuximab substantially improves outcomes in patients with metastatic colorectal cancer with FCGR2A biomarker.

ASCO 2016 Annual Meeting

Live coverage from ASCO 2016.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

MicroRNA Down-regulate After Exposure to UV Radiation in Melanocytes of Women with a History of Melanoma

MicroRNA Down-regulate After Exposure to UV Radiation in Melanocytes of Women with a History of Melanoma

MicroRNAs in the melanocytes of women with a history of melanoma were down-regulated when exposed to ultraviolet radiation.

Immune Therapies May Offer Promise for Hormone-receptor-positive Breast Cancer

Immune Therapies May Offer Promise for Hormone-receptor-positive Breast Cancer

Researchers argue that immune therapies that target hormone-receptor-positive breast cancer is not the "dead end" it was once believed to be.

Feature Articles

Melanoma Patients May Not Require Complete Lymph Node Dissection

Melanoma Patients May Not Require Complete Lymph Node Dissection

A phase 3 trial of patients with cutaneous melanoma found no difference in distant metastasis-free survival between those who underwent complete lymph node dissection and those who did not.

Pembrolizumab Is Promising for Future Merkel Cell Cancer Treatment

Pembrolizumab Is Promising for Future Merkel Cell Cancer Treatment

For Merkel-cell cancers—the deadliest and rarest type—there are no approved drugs once surgery and radiation fail.

Managing Cardiovascular Complications in Oncology Treatment

Managing Cardiovascular Complications in Oncology Treatment

Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.

Q&A With Elias Jabbour, MD, Highlights Evolving Treatment Landscape for CML, Pricing Barriers

Q&A With Elias Jabbour, MD, Highlights Evolving Treatment Landscape for CML, Pricing Barriers

Dr Jabbour discusses clinical decision making for chronic myeloid leukemia and the high price of newly approved drugs in an interview with Cancer Therapy Advisor.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters